Natera, Inc. (NASDAQ:NTRA) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 18,607.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,916 shares of the medical research company's stock after buying an additional 119,275 shares during the period. GAMMA Investing LLC owned approximately 0.09% of Natera worth $16,957,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after acquiring an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP boosted its holdings in Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 6,702 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.03, for a total value of $978,693.06. Following the completion of the sale, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,695,784.62. This represents a 3.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gail Boxer Marcus sold 4,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,433,183.76. This represents a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,275 shares of company stock valued at $10,075,783 over the last ninety days. Insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NTRA shares. Robert W. Baird boosted their price objective on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Barclays lifted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research note on Friday, February 28th. Finally, Royal Bank of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and an average target price of $184.63.

Natera Price Performance

Shares of NASDAQ NTRA traded up $0.43 during trading on Monday, hitting $164.19. The company had a trading volume of 785,454 shares, compared to its average volume of 1,407,113. The firm has a market capitalization of $22.42 billion, a price-to-earnings ratio of -93.29 and a beta of 1.74. The stock has a fifty day simple moving average of $151.77 and a two-hundred day simple moving average of $158.53. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same period in the previous year, the firm posted ($0.56) EPS. Natera's revenue was up 36.5% compared to the same quarter last year. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.